{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T05:11:27Z","timestamp":1771823487177,"version":"3.50.1"},"reference-count":41,"publisher":"Jaypee Brothers Medical Publishing","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.59556\/japi.74.1302","type":"journal-article","created":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T04:35:33Z","timestamp":1771821333000},"page":"46-50","source":"Crossref","is-referenced-by-count":0,"title":["Future Directions and Innovations in Mineralocorticoid Receptor Antagonist Therapy"],"prefix":"10.59556","volume":"74","author":[{"given":"Shashank","family":"Joshi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mangesh","family":"Tiwaskar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jayanta","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kunhali","family":"K","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vishal","family":"Rastogi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sunil","family":"Antony","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"AP","family":"Nandhakumar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Agam","family":"Vora","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A Ganesh","family":"Raja","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A","family":"Anitha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ramkesh S","family":"Parmar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Febin","family":"Francis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amarnath","family":"Sugumaran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Senthilnathan","family":"Mohanasundaram","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2914","reference":[{"issue":"(18):","key":"key20260223043528_B1","doi-asserted-by":"crossref","first-page":"1835\u2013","DOI":"10.1016\/j.jacc.2023.03.393","article-title":"2023 ACC expert consensus decision pathway on management of heart failure with preserved ejection fraction.","volume":"81","author":"Kittleson","year":"2023;","journal-title":"JACC"},{"issue":"(18):","key":"key20260223043528_B2","first-page":"e895\u2013","article-title":"2022 AHA\/ACC\/HFSA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association joint committee on clinical practice guidelines.","volume":"145","author":"Heidenreich","year":"2022;","journal-title":"Circulation"},{"issue":"(8):","key":"key20260223043528_B3","first-page":"11\u2013","article-title":"Heart failure with preserved ejection fraction: management guidelines (from Heart Failure Association of India, endorsed by Association of Physicians of India).","volume":"70","author":"Harikrishnan","year":"2022;","journal-title":"J Assoc Physicians India"},{"issue":"(2):","key":"key20260223043528_B4","first-page":"148\u2013","article-title":"2024 guidelines of the Taiwan Society of Cardiology for the diagnosis and treatment of heart failure with preserved ejection fraction.","volume":"40","author":"Li","year":"2024;","journal-title":"Acta Cardiol Sin"},{"issue":"(3):","key":"key20260223043528_B5","doi-asserted-by":"crossref","first-page":"133.","DOI":"10.4103\/jpcs.jpcs_1_18","article-title":"Heart failure guidelines for India: update 2017.","volume":"3","author":"Seth","year":"2017;","journal-title":"J Pract Cardiovasc Sci"},{"issue":"(2):","key":"key20260223043528_B6","doi-asserted-by":"crossref","first-page":"243\u2013","DOI":"10.1007\/s40119-024-00367-4","article-title":"Management of heart failure in a resource-limited setting: expert opinion from India.","volume":"13","author":"Jain","year":"2024;","journal-title":"Cardiol Ther"},{"issue":"(1):","key":"key20260223043528_B7","first-page":"4\u2013","article-title":"2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure.","volume":"24","author":"McDonagh","year":"2022;","journal-title":"Eur J Heart Fail"},{"issue":"1:","key":"key20260223043528_B8","doi-asserted-by":"crossref","first-page":"S1\u2013","DOI":"10.1016\/j.ihj.2018.05.003","article-title":"CSI position statement on management of heart failure in India.","volume":"70","author":"Guha","year":"2018;","journal-title":"Indian Heart J"},{"issue":"(5):","key":"key20260223043528_B9","doi-asserted-by":"crossref","first-page":"455\u2013","DOI":"10.1093\/eurheartj\/ehv464","article-title":"Influence of ejection fraction on outcomes and efficacy of spironolactone in patients with heart failure with preserved ejection fraction.","volume":"37","author":"Solomon","year":"2016;","journal-title":"Eur Heart J"},{"key":"key20260223043528_B10","unstructured":"Borlaung B, Colucci W. (2023). Treatment and prognosis of heart failure with preserved ejection fraction. [online] Available from https:\/\/www.uptodate.com\/contents\/treatment-and-prognosis-of-heart-failure-with-preserved-ejection-fraction\/print [Last accessed December, 2025]."},{"issue":"(5S):","key":"key20260223043528_B11","first-page":"S1\u2013","article-title":"KDIGO 2022 clinical practice guideline for diabetes management in chronic kidney disease.","volume":"102","author":"Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group.","year":"2022;","journal-title":"Kidney Int"},{"issue":"(37):","key":"key20260223043528_B12","doi-asserted-by":"crossref","first-page":"3627\u2013","DOI":"10.1093\/eurheartj\/ehad195","article-title":"2023 focused update of the 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: developed by the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) with the special contribution of the Heart Failure Association (HFA) of the ESC.","volume":"44","author":"McDonagh","year":"2023;","journal-title":"Eur Heart J"},{"issue":"(3):","key":"key20260223043528_B13","doi-asserted-by":"crossref","first-page":"e002493.","DOI":"10.1161\/JAHA.115.002493","article-title":"Barriers to adoption of mineralocorticoid receptor antagonists in patients with heart failure: a mixed-methods study.","volume":"5","author":"Dev","year":"2016;","journal-title":"J Am Heart Assoc"},{"issue":"(1):","key":"key20260223043528_B14","doi-asserted-by":"crossref","first-page":"74.","DOI":"10.5334\/gh.1355","article-title":"Use of guideline-recommended heart failure drugs in high-, middle-, and low-income countries: a systematic review and meta-analysis.","volume":"19","author":"Satheesh","year":"2024;","journal-title":"Glob Heart"},{"key":"key20260223043528_B15","doi-asserted-by":"crossref","first-page":"133\u2013","DOI":"10.1016\/j.ijcard.2015.11.183","article-title":"Heart failure in Africa, Asia, the Middle East and South America: the INTER-CHF study.","volume":"204:","author":"Dokainish","year":"2016;","journal-title":"Int J Cardiol"},{"issue":"(7):","key":"key20260223043528_B16","doi-asserted-by":"crossref","first-page":"e665\u2013","DOI":"10.1016\/S2214-109X(17)30196-1","article-title":"Global mortality variations in patients with heart failure: results from the International Congestive Heart Failure (INTER-CHF) prospective cohort study.","volume":"5","author":"Dokainish","year":"2017;","journal-title":"Lancet Glob Health"},{"issue":"(9):","key":"key20260223043528_B17","doi-asserted-by":"crossref","first-page":"e1008\u2013","DOI":"10.1016\/S2214-109X(18)30306-1","article-title":"Prescribing patterns of evidence-based heart failure pharmacotherapy and outcomes in the ASIAN-HF registry: a cohort study.","volume":"6","author":"Teng","year":"2018;","journal-title":"Lancet Glob Health"},{"issue":"(8):","key":"key20260223043528_B18","doi-asserted-by":"crossref","first-page":"794\u2013","DOI":"10.1002\/ejhf.283","article-title":"Clinical presentation, management, in-hospital and 90-day outcomes of heart failure patients in Trivandrum, Kerala, India: the Trivandrum Heart Failure Registry.","volume":"17","author":"Harikrishnan","year":"2015;","journal-title":"Eur J Heart Fail"},{"issue":"(8):","key":"key20260223043528_B19","doi-asserted-by":"crossref","first-page":"e1001699.","DOI":"10.1371\/journal.pmed.1001699","article-title":"Heart failure care in low- and middle-income countries: a systematic review and meta-analysis.","volume":"11","author":"Callender","year":"2014;","journal-title":"PLoS Med"},{"issue":"(8):","key":"key20260223043528_B20","doi-asserted-by":"crossref","first-page":"1727\u2013","DOI":"10.1002\/ejhf.3294","article-title":"Balcinrenone plus dapagliflozin in patients with heart failure and chronic kidney disease: results from the phase 2b MIRACLE trial.","volume":"26","author":"Lam","year":"2024;","journal-title":"Eur J Heart Fail"},{"issue":"(4):","key":"key20260223043528_B21","doi-asserted-by":"crossref","first-page":"201\u2013","DOI":"10.1016\/j.tem.2015.01.007","article-title":"Emerging cardiovascular indications of mineralocorticoid receptor antagonists.","volume":"26","author":"Parviz","year":"2015;","journal-title":"Trends Endocrinol Metab"},{"issue":"(8):","key":"key20260223043528_B22","doi-asserted-by":"crossref","first-page":"e14206.","DOI":"10.1111\/eci.14206","article-title":"Mineralocorticoid receptor antagonists in kidney transplantation.","volume":"54","author":"Kanbay","year":"2024;","journal-title":"Eur J Clin Invest"},{"issue":"(3):","key":"key20260223043528_B23","first-page":"839\u2013","article-title":"Mineralocorticoid receptor blockage in kidney transplantation: too much of a good thing or not?","volume":"57","author":"Afsar","year":"2025;","journal-title":"Int Urol Nephrol"},{"issue":"(2):","key":"key20260223043528_B24","doi-asserted-by":"crossref","first-page":"57.","DOI":"10.3390\/jpm15020057","article-title":"Mineralocorticoid receptor antagonists and cognitive outcomes in cardiovascular disease and beyond: a systematic review.","volume":"15","author":"Pastena","year":"2025;","journal-title":"J Pers Med"},{"issue":"(10):","key":"key20260223043528_B25","doi-asserted-by":"crossref","first-page":"756\u2013","DOI":"10.1093\/eurheartj\/ehad811","article-title":"Mineralocorticoid receptor antagonists and atrial fibrillation: a meta-analysis of clinical trials.","volume":"45","author":"Oraii","year":"2024;","journal-title":"Eur Heart J"},{"issue":"(6):","key":"key20260223043528_B26","doi-asserted-by":"crossref","first-page":"884\u2013","DOI":"10.1007\/s00392-023-02349-3","article-title":"Incidence and progression of atrial fibrillation in patients with and without heart failure using mineralocorticoid receptor antagonists: a meta-analysis.","volume":"113","author":"Sampaio Rodrigues","year":"2024;","journal-title":"Clin Res Cardiol"},{"issue":"(9):","key":"key20260223043528_B27","doi-asserted-by":"crossref","first-page":"102742.","DOI":"10.1016\/j.cpcardiol.2024.102742","article-title":"Effects of mineralocorticoid receptor antagonists on new-onset or recurrent atrial fibrillation: a Bayesian and frequentist network meta-analysis of randomized trials.","volume":"49","author":"Karakasis","year":"2024;","journal-title":"Curr Probl Cardiol"},{"issue":"(23):","key":"key20260223043528_B28","doi-asserted-by":"crossref","first-page":"3025\u2013","DOI":"10.1161\/CIRCULATIONAHA.104.503706","article-title":"Conditional mineralocorticoid receptor expression in the heart leads to life-threatening arrhythmias.","volume":"111","author":"Ouvrard-Pascaud","year":"2005;","journal-title":"Circulation"},{"issue":"(9):","key":"key20260223043528_B29","doi-asserted-by":"crossref","first-page":"572\u2013","DOI":"10.1002\/clc.20762","article-title":"The effect of aldosterone antagonists for ventricular arrhythmia: a meta-analysis.","volume":"33","author":"Wei","year":"2010;","journal-title":"Clin Cardiol"},{"issue":"(4):","key":"key20260223043528_B30","doi-asserted-by":"crossref","first-page":"739\u2013","DOI":"10.1161\/CIRCEP.112.970566","article-title":"The effect of spironolactone on ventricular tachyarrhythmias in patients with implantable cardioverter-defibrillators.","volume":"5","author":"Zarraga","year":"2012;","journal-title":"Circ Arrhythm Electrophysiol"},{"issue":"(10):","key":"key20260223043528_B31","doi-asserted-by":"crossref","first-page":"709\u2013","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.","volume":"341","author":"Pitt","year":"1999;","journal-title":"N Engl J Med"},{"issue":"(1):","key":"key20260223043528_B32","doi-asserted-by":"crossref","first-page":"11\u2013","DOI":"10.1056\/NEJMoa1009492","article-title":"Eplerenone in patients with systolic heart failure and mild symptoms.","volume":"364","author":"Zannad","year":"2011;","journal-title":"N Engl J Med"},{"issue":"(14):","key":"key20260223043528_B33","doi-asserted-by":"crossref","first-page":"1309\u2013","DOI":"10.1056\/NEJMoa030207","article-title":"Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.","volume":"348","author":"Pitt","year":"2003;","journal-title":"N Engl J Med"},{"issue":"(3):","key":"key20260223043528_B34","doi-asserted-by":"crossref","first-page":"277\u2013","DOI":"10.1093\/eurjhf\/hfs173","article-title":"Plasma aldosterone levels are elevated in patients with pulmonary arterial hypertension in the absence of left ventricular heart failure: a pilot study.","volume":"15","author":"Maron","year":"2013;","journal-title":"Eur J Heart Fail"},{"issue":"(2):","key":"key20260223043528_B35","doi-asserted-by":"crossref","first-page":"200\u2013","DOI":"10.1086\/675984","article-title":"The role of the renin-angiotensin-aldosterone system in the pathobiology of pulmonary arterial hypertension (2013 Grover Conference Series).","volume":"4","author":"Maron","year":"2014;","journal-title":"Pulm Circ"},{"issue":"(5):","key":"key20260223043528_B36","doi-asserted-by":"crossref","first-page":"720\u2013","DOI":"10.1016\/j.amjcard.2013.04.051","article-title":"Effectiveness of spironolactone plus ambrisentan for treatment of pulmonary arterial hypertension (from the [ARIES] study 1 and 2 trials).","volume":"112","author":"Maron","year":"2013;","journal-title":"Am J Cardiol"},{"key":"key20260223043528_B37","doi-asserted-by":"crossref","first-page":"91.","DOI":"10.1186\/1745-6215-14-91","article-title":"A pilot study of the effect of spironolactone therapy on exercise capacity and endothelial dysfunction in pulmonary arterial hypertension: study protocol for a randomized controlled trial.","volume":"14:","author":"Elinoff","year":"2013;","journal-title":"Trials"},{"issue":"(2):","key":"key20260223043528_B38","first-page":"CD013109.","article-title":"Aldosterone antagonists for people with chronic kidney disease requiring dialysis.","volume":"2","author":"Hasegawa","year":"2021;","journal-title":"Cochrane Database Syst Rev"},{"issue":"(9):","key":"key20260223043528_B39","doi-asserted-by":"crossref","first-page":"1845\u2013","DOI":"10.1161\/HYPERTENSIONAHA.124.22642","article-title":"Clinical management of primary aldosteronism: an update.","volume":"81","author":"Rossi","year":"2024;","journal-title":"Hypertension"},{"issue":"(5):","key":"key20260223043528_B40","doi-asserted-by":"crossref","first-page":"1252\u2013","DOI":"10.1161\/HYPERTENSIONAHA.107.109439","article-title":"Aldosterone and metabolic syndrome.","volume":"51","author":"Krug","year":"2008;","journal-title":"Hypertension"},{"issue":"(1):","key":"key20260223043528_B41","doi-asserted-by":"crossref","first-page":"16\u2013","DOI":"10.1097\/MNH.0000000000000189","article-title":"Aldosterone in vascular and metabolic dysfunction.","volume":"25","author":"Luther","year":"2016;","journal-title":"Curr Opin Nephrol Hypertens"}],"container-title":["Journal of The Association of Physicians of India"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T04:35:40Z","timestamp":1771821340000},"score":1,"resource":{"primary":{"URL":"https:\/\/japi.org\/article\/japi-74-1-s1-46"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":41,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["10.59556\/japi.74.1302"],"URL":"https:\/\/doi.org\/10.59556\/japi.74.1302","relation":{},"ISSN":["0004-5772"],"issn-type":[{"value":"0004-5772","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]}}}